Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke
Status:
COMPLETED
Trial end date:
2025-04-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.
Phase:
PHASE1
Details
Lead Sponsor:
Allife Medical Science and Technology Co., Ltd.
Collaborators:
Beijing Tiantan Hospital Linfen Central Hospital Linyi People's Hospital Peking University Third Hospital Xuanwu Hospital, Beijing